Methods Patients with FD randomly received either itopride 50 mg or DA-9701 30 mg tid
after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were
analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the
overall treatment effect. Impact on patients' quality of life was assessed using the Nepean
Dyspepsia Index (NDI) questionnaire. Results We randomly assigned 464 patients with 455
having outcome data. The difference of the composite score change of the 8 symptoms …

ScholarWorks@SUNGKYUNKWAN UNIVERSITY: Randomized, controlled, multi-center trial
comparing the safety and efficacy of DA-9701 and itopride hydrochloride in patients with
functional dyspepsia: a non-inferiority trial … Randomized, controlled, multi-center trial
comparing the safety and efficacy of DA-9701 and itopride hydrochloride in patients with
functional dyspepsia: a non-inferiority trial …